Senores Pharmaceuticals Share Price Today

Senores Pharmaceuticals AGM passes all resolutions; public dissent on ESOP

All six resolutions passed at Senores Pharmaceuticals' 9th AGM held on September 25, 2026. Public institutions voted 46.71% against Arpit Deepakkumar Shah's re-election. ESOP scheme approval saw 46.45% opposition from public institutions but passed with 93.81% total support. Promoter group voted 100% in favour of all resolutions.

Senores Pharmaceuticals clears USFDA inspection at subsidiary Apnar Pharma

Senores Pharmaceuticals completed a USFDA inspection at its subsidiary Apnar Pharma. Inspectors raised one minor procedural observation during the inspection. No issues related to Good Manufacturing Practices (GMP) were identified.

Senores Pharmaceuticals files FY26 sustainability report with exchanges

Senores Pharmaceuticals filed its FY26 BRSR with BSE and NSE on September 3, 2026. Turnover stood at ₹10,609 lakh with exports contributing 43.95% of revenue. Total energy consumption rose to 22.50 TJ from 2.43 TJ in the prior year. Related-party sales increased to 48.2% while purchases fell to 3.2%. GHG emissions reached 1,738 metric tonnes of CO2 equivalent.

Senores Pharmaceuticals schedules 9th AGM for September 25, 2026

Senores Pharmaceuticals schedules its 9th AGM for September 25, 2026. The meeting will be held via video conferencing at 11:30 am. Remote e-voting opens on September 22 and closes on September 24. The cut-off date for voting eligibility is September 18, 2026. Annual Report for FY26 is available electronically to registered members.

Senores Pharmaceuticals to host investor conference in Mumbai on Sep 2

Senores Pharmaceuticals will host an investor conference on September 2, 2026. The event is hosted by Elara Capital and held physically in Mumbai. Meetings include both group sessions and one-on-one interactions. Discussions will rely only on publicly available information. No unpublished price sensitive information will be shared.

Senores Pharma approves Mexico, Canada subsidiaries and ESOS

Senores Pharma approved wholly owned subsidiaries in Mexico and Canada for pharma distribution. ESOS 2026 approved covering 472,000 options, representing 1% of fully diluted equity. Dr. Viranchi Arvindbhai Shah appointed as Additional Independent Director. Mrs. Shilpa Sharma appointed as Company Secretary and Compliance Officer. Subsidiaries aim to support strategic business objectives in international markets.